Atyr Pharma Inc. (NASDAQ:LIFE)’s share price dropped 1.3% during mid-day trading on Thursday . The stock traded as low as $2.94 and last traded at $3.02, with a volume of 1,003,159 shares traded. The stock had previously closed at $3.06.

LIFE has been the topic of several recent research reports. William Blair lowered Atyr Pharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 31st. Zacks Investment Research upgraded Atyr Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, May 24th. Finally, BMO Capital Markets reiterated a “hold” rating on shares of Atyr Pharma in a research report on Thursday, May 12th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Atyr Pharma has an average rating of “Hold” and an average price target of $23.75.

The firm’s market cap is $68.69 million. The firm has a 50 day moving average price of $2.89 and a 200 day moving average price of $4.15.

Atyr Pharma (NASDAQ:LIFE) last released its quarterly earnings data on Wednesday, May 11th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.02. Equities research analysts anticipate that Atyr Pharma Inc. will post ($2.79) earnings per share for the current year.

In other news, insider Grove Matsuoka bought 12,412 shares of the firm’s stock in a transaction that occurred on Wednesday, May 11th. The shares were bought at an average cost of $3.04 per share, for a total transaction of $37,732.48. Following the completion of the transaction, the insider now owns 2,412 shares of the company’s stock, valued at $7,332.48. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.